AU2020261423B2 - Heterocyclic inhibitors of tyrosine kinase - Google Patents

Heterocyclic inhibitors of tyrosine kinase

Info

Publication number
AU2020261423B2
AU2020261423B2 AU2020261423A AU2020261423A AU2020261423B2 AU 2020261423 B2 AU2020261423 B2 AU 2020261423B2 AU 2020261423 A AU2020261423 A AU 2020261423A AU 2020261423 A AU2020261423 A AU 2020261423A AU 2020261423 B2 AU2020261423 B2 AU 2020261423B2
Authority
AU
Australia
Prior art keywords
compound
iii
chosen
egfr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020261423A
Other languages
English (en)
Other versions
AU2020261423A1 (en
Inventor
Jason Cross
John Heymach
Philip Jones
Monique NILSSON
Jacqulyne ROBICHAUX
Jay THEROFF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2020261423A1 publication Critical patent/AU2020261423A1/en
Application granted granted Critical
Publication of AU2020261423B2 publication Critical patent/AU2020261423B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020261423A 2019-04-25 2020-04-24 Heterocyclic inhibitors of tyrosine kinase Active AU2020261423B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838696P 2019-04-25 2019-04-25
US62/838,696 2019-04-25
PCT/US2020/029849 WO2020219904A1 (en) 2019-04-25 2020-04-24 Heterocyclic inhibitors of tyrosine kinase

Publications (2)

Publication Number Publication Date
AU2020261423A1 AU2020261423A1 (en) 2021-12-09
AU2020261423B2 true AU2020261423B2 (en) 2026-01-29

Family

ID=72941423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020261423A Active AU2020261423B2 (en) 2019-04-25 2020-04-24 Heterocyclic inhibitors of tyrosine kinase

Country Status (7)

Country Link
US (1) US11365189B2 (enExample)
EP (1) EP3962908A4 (enExample)
JP (1) JP7601788B2 (enExample)
CN (2) CN118852118A (enExample)
AU (1) AU2020261423B2 (enExample)
CA (1) CA3137901A1 (enExample)
WO (1) WO2020219904A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
CA3137901A1 (en) 2019-04-25 2020-10-29 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
US20240246940A1 (en) * 2021-04-22 2024-07-25 Voronoi Inc. Heteroaryl derivative compound and use thereof
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
WO2022266425A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 3-cyano-quinoline derivatives and uses thereof
AR126849A1 (es) * 2021-08-24 2023-11-22 Arthrosi Therapeutics Inc Compuestos de quinazolina para tratamiento de enfermedad
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130071452A1 (en) * 2010-06-11 2013-03-21 Hanmi Science Co., Ltd Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
EP2167492B1 (en) * 2007-06-05 2015-10-14 Hanmi Science Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
EP3050880A1 (en) * 2013-09-28 2016-08-03 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Quinazoline derivative and preparation method therefor
WO2019165003A1 (en) * 2018-02-20 2019-08-29 Dawei Zhang Substituted quinolines useful as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492536B1 (de) * 2002-03-30 2012-05-09 Boehringer Ingelheim Pharma GmbH & Co.KG 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren
ES2775614T3 (es) 2015-03-20 2020-07-27 Chai Tai Tianqing Pharmaceutical Group Co Ltd Sales de derivado de quinazolina y método de preparación de las mismas
CN113149960A (zh) 2016-08-25 2021-07-23 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体
CA3137901A1 (en) 2019-04-25 2020-10-29 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167492B1 (en) * 2007-06-05 2015-10-14 Hanmi Science Co., Ltd. Novel amide derivative for inhibiting the growth of cancer cells
US20130071452A1 (en) * 2010-06-11 2013-03-21 Hanmi Science Co., Ltd Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
EP3050880A1 (en) * 2013-09-28 2016-08-03 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Quinazoline derivative and preparation method therefor
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
WO2019165003A1 (en) * 2018-02-20 2019-08-29 Dawei Zhang Substituted quinolines useful as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, E. ET AL.: "Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/ tandem mass spectrometry", RAPID COMMUN. MASS SPECTROM, vol. 27, no. 11, 2013, pages 1183 - 1195 *

Also Published As

Publication number Publication date
CN114026083A (zh) 2022-02-08
JP2022529518A (ja) 2022-06-22
US11365189B2 (en) 2022-06-21
EP3962908A1 (en) 2022-03-09
EP3962908A4 (en) 2022-10-26
AU2020261423A1 (en) 2021-12-09
CN118852118A (zh) 2024-10-29
US20200354343A1 (en) 2020-11-12
JP7601788B2 (ja) 2024-12-17
CA3137901A1 (en) 2020-10-29
WO2020219904A1 (en) 2020-10-29
CN114026083B (zh) 2024-07-09

Similar Documents

Publication Publication Date Title
JP7579402B2 (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
JP7601788B2 (ja) チロシンキナーゼの複素環式阻害剤
US11690850B2 (en) Inhibitors of receptor interacting protein kinase I for the treatment of disease
CA3024706A1 (en) Heterocyclic inhibitors of ptpn11
KR102653599B1 (ko) 질환 치료용 mct4 저해제
EP3316887B1 (en) Gls1 inhibitors for treating disease
WO2016004417A1 (en) Gls1 inhibitors for treating disease
US12559497B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2020219906A1 (en) Heterocyclic inhibitors of tyrosine kinase
BRPI0613644A2 (pt) moduladores de tieno pirimidina e tieno pirimidina cinase
WO2018213777A1 (en) Heterocyclic inhibitors of kdm5 for the treatment of disease
EP4221708A1 (en) Imidazopiperazine inhibitors of transcription activating proteins
HK40015139A (en) Heterocyclic inhibitors of mct4
HK40015139B (en) Heterocyclic inhibitors of mct4